Figure 1 from Ex Vivo Tumor-Derived Organoid Pharmacotyping Identifies Personalized Therapeutic Options for Patients with Biliary Tract Cancer

Le résumé fourni par la source

Description of PARIS assay workflow and characterization of the BTC cohort. A, Fresh tumor specimens from patients with BTC were sent to SEngine Precision Medicine for the derivation of organoid cultures (left). The reference organoid photo shown was derived from an ascites sample from a 52-year-old female patient with iCCA (BTC-1). Immunofluorescent staining was performed for DAPI (blue) and pan-keratin (green). The organoid cultures then underwent WES and drug screening, and a ranked drug list was derived from the results (middle). This ranking includes information on targeted, endocrine, and chemotherapeutic agents and can be used by clinicians to guide treatment decisions (right). B, Clinical diagnoses of the cohort of patients with BTC. CCA-NOS, CCA, not otherwise specified; GBC, gallbladder carcinoma. C, Clinical stage of the patients with BTC. D, Clinical procedures used to collect the tumor organoids. E, Anatomic origin of the specimens. F, Treatment exposure history of patients with BTC prior to specimen collection. Any chemotherapeutic treatment, including adjuvant treatment, was counted as a previous treatment. G, Success rates of organoid establishment according to the clinical procedure used to obtain the specimen. H, Success rates of organoid establishment according to the anatomic site of origin. I, Overall success rates of organoid culture derivation and subsequent drug screening. The success rate was calculated for all specimens, including those that were found to have insufficient tumor content. The drug screening success rate was calculated from the number of established organoid cultures. [A, Created in BioRender. Kemp, C. (2026) https://BioRender.com/kv0dbe7.]

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.